Myths, reality and future of mesenchymal stem cell therapy

  • R. A. Poltavtseva
  • A. V. Poltavtsev
  • G. V. Lutsenko
  • E. V. Svirshchevskaya


Mesenchymal stem cell (MSC) therapy represents an alternative approach for tissue regeneration and inflammation control. In spite of a huge amount of preclinical data that has been accumulated on the therapeutic properties of MSCs, there are many conflicting results, possibly due to differences in the properties of MSCs obtained from different sources or underestimated mechanisms of MSC in vivo behavior. This review consolidates the in vivo effects of MSC therapy, discusses the fate of MSCs after intravascular and local delivery and proposes possible trends in MSC therapy.


Mesenchymal stem cells Cell therapy Exosomes Liposomes Diabetes mellitus 


Funding information

This work was supported by the Russian Science Foundation grant no. 14-25-00179.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement on the welfare of animals

All procedures involving animals were in accordance with the ethical standards of the institution.


  1. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815–1822CrossRefGoogle Scholar
  2. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S (2012) Mesenchymal stem cell induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10(5):544–555CrossRefGoogle Scholar
  3. Akyurekli C, Le Y, Richardson RB, Fergusson D, Tay J, Allan DS (2015) A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev 11(1):150–160. CrossRefPubMedGoogle Scholar
  4. Allen TA, Gracieux D, Talib M, Tokarz DA, Hensley MT, Cores J, Vandergriff A, Tang J, de Andrade JB, Dinh PU, Yoder JA, Cheng K (2017) Angiopellosis as an alternative mechanism of cell extravasation. Stem Cells 35(1):170–180. CrossRefPubMedGoogle Scholar
  5. Barrow AD, Trowsdale J (2006) You say ITAM and I say ITIM, let’s call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 36(7):1646–1653CrossRefGoogle Scholar
  6. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1):42–48CrossRefGoogle Scholar
  7. Bartolucci JG, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo PG, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M (2017) Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial). Circ Res. CrossRefGoogle Scholar
  8. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105(5):2214–2219CrossRefGoogle Scholar
  9. Bhansali A, Asokumar P, Walia R, Bhansali S, Gupta V, Jain A, Sachdeva N, Sharma RR, Marwaha N, Khandelwal N (2014) Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant 23(9):1075–1085CrossRefGoogle Scholar
  10. Borregaard N (2010) Neutrophils, from marrow to microbes. Immunity 33:657–670CrossRefGoogle Scholar
  11. Brazil JC, Parkos CA (2016) Pathobiology of neutrophil-epithelial interactions. Immunol Rev 273(1):94–111. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Burk J, Berner D, Brehm W, Hillmann A, Horstmeier C, Josten C, Paebst F, Rossi G, Schubert S, Ahrberg AB (2016) Long-term cell tracking following local injection of mesenchymal stromal cells in the equine model of induced tendon disease. Cell Transplant 25(12):2199–2211. CrossRefPubMedGoogle Scholar
  13. Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M (2017) Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial. Circ Res 120(2):332–340. CrossRefPubMedGoogle Scholar
  14. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J (2016) Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care 39(1):149–157. CrossRefPubMedGoogle Scholar
  15. Cui R, Rekasi H, Hepner-Schefczyk M, Fessmann K, Petri RM, Bruderek K, Brandau S, Jäger M, Flohé SB (2016) Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Res Ther 7(1):88. CrossRefPubMedPubMedCentralGoogle Scholar
  16. Cui X, He Z, Liang Z, Chen Z, Wang H, Zhang J (2017a) Exosomes from adipose-derived mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through Wnt/β-catenin signaling pathway. J Cardiovasc Pharmacol 70(4):225–231. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Cui LL, Nitzsche F, Pryazhnikov E, Tibeykina M, Tolppanen L, Rytkönen J, Huhtala T, Mu JW, Khiroug L, Boltze J, Jolkkonen J (2017b) Integrin α4 overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection. Stroke. CrossRefGoogle Scholar
  18. Daëron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH (1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3(5):635–646CrossRefGoogle Scholar
  19. De Becker A, Riet IV (2016) Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells 8(3):73–87. CrossRefPubMedPubMedCentralGoogle Scholar
  20. Dollet PE, Ravau J, André F, Najimi M, Sokal E, Lombard C (2016) Comprehensive screening of cell surface markers expressed by adult-derived human liver stem/progenitor cells harvested at passage 5: potential implications for engraftment. Stem Cells Int 2016:9302537CrossRefGoogle Scholar
  21. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317CrossRefGoogle Scholar
  22. Drommelschmidt K, Serdar M, Bendix I, Herz J, Bertling F, Prager S, Keller M, Ludwig AK, Duhan V, Radtke S, de Miroschedji K, Horn PA, van de Looij Y, Giebel B, Felderhoff-Müser U (2017) Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury. Brain Behav Immun 60:220–232. CrossRefPubMedGoogle Scholar
  23. Evans CE, Palazon A, Sim J, Tyrakis PA, Prodger A, Lu X, Chan S, Bendahl PO, Belting M, Von Euler L, Rundqvist H, Johnson RS, Branco C (2017) Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis. Biol Open 6(5):688–697. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N (2018) Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. Friede T, ed. PLoS One 13(5):e0195891. CrossRefPubMedPubMedCentralGoogle Scholar
  25. Florea V, Rieger AC, Difede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Lowery MH, Byrnes J, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid FA, Vidro-Casiano M, Saltzman R, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM (2017) Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (the TRIDENT study). Circ Res. CrossRefGoogle Scholar
  26. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, Westien I, Wang W, Yerebakan C, Li W, Gaebel R, Li RK, Vollmar B, Steinhoff G, Ma N (2009) Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res 77(3):370–376. CrossRefPubMedGoogle Scholar
  27. Galipeau J, Krampera M (2015) The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy 17(2):125–127. CrossRefPubMedGoogle Scholar
  28. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L (2016) International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18(2):151–159. CrossRefPubMedGoogle Scholar
  29. Gallois A, Silva I, Osman I, Bhardwaj N (2015) Reversal of natural killer cell exhaustion by TIM-3 blockade. Oncoimmunology 3(12):e946365CrossRefGoogle Scholar
  30. Ge J, Guo L, Wang S, Zhang Y, Cai T, Zhao RC, Wu Y (2014) The size of mesenchymal stem cells is a significant cause of vascular obstructions and stroke. Stem Cell Rev 10(2):295–303. CrossRefPubMedGoogle Scholar
  31. Gimble JM, Katz AJ, Bunnell BA (2007) Adipose-derived stem cells for regenerative medicine. Circ Res 100:1249–1260CrossRefGoogle Scholar
  32. Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, Mageto YN, Mendizabal A, Hare JM (2017) Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial chest. 151(5):971–981. CrossRefGoogle Scholar
  33. Gleeson BM, Martin K, Ali MT, Kumar AH, Pillai MG, Kumar SP, O’Sullivan JF, Whelan D, Stocca A, Khider W, Barry FP, O’Brien T, Caplice NM (2015) Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: amelioration by antithrombin therapy. Stem Cells 33(9):2726–2737. CrossRefPubMedGoogle Scholar
  34. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7):2821–2827CrossRefGoogle Scholar
  35. Gronthos S, Graves SE, Ohta S, Simmons PJ (1994) The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood 84:4164–4173PubMedGoogle Scholar
  36. Gronthos S, Fitter S, Diamond P, Simmons PJ, Itescu S, Zannettino AC (2007) A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells Dev 16(6):953–963CrossRefGoogle Scholar
  37. Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW (2017) Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol 69(5):526–537. CrossRefPubMedGoogle Scholar
  38. Henry TD, Schaer GL, DeMaria A, Recker D, Remmers AE, Goodrich J, Patel AN (2016a) The ixCELL-DCM trial: rationale and design. Cell Transplant 25(9):1689–1699CrossRefGoogle Scholar
  39. Henry TD, Traverse JH, Hammon BL, East CA, Bruckner B, Remmers AE, Recker D, Bull DA, Patel AN (2016b) Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 115(8):730–737. CrossRefGoogle Scholar
  40. Hu GW, Li Q, Niu X, Hu B, Liu J, Zhou SM, Guo SC, Lang HL, Zhang CQ, Wang Y, Deng ZF (2015) Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Res Ther 6:10. CrossRefPubMedPubMedCentralGoogle Scholar
  41. Huang JH, Yin XM, Xu Y, Xu CC, Lin X, Ye FB, Cao Y, Lin FY (2017) Systemic administration of exosomes released from mesenchymal stromal cells attenuates apoptosis, inflammation, and promotes angiogenesis after spinal cord injury in rats. J Neurotrauma. CrossRefGoogle Scholar
  42. Humphrey JH (1986) Regulation of in vivo immune responses: few principles and much ignorance. CIBA Found Symp 119:6–24PubMedGoogle Scholar
  43. Hunt JS, Fishback JL, Andrews GK, Wood GW (1988) Expression of class I HLA genes by trophoblast cells. Analysis by in situ hybridization. J Immunol 140(4):1293–1299PubMedGoogle Scholar
  44. Jurisic G, Iolyeva M, Proulx ST, Halin C, Detmar M (2010) Thymus cell antigen 1 (Thy1, CD90) is expressed by lymphatic vessels and mediates cell adhesion to lymphatic endothelium. Exp Cell Res 316:2982–2992CrossRefGoogle Scholar
  45. Kalinina N, Kharlampieva D, Loguinova M, Butenko I, Pobeguts O, Efimenko A, Ageeva L, Sharonov G, Ischenko D, Alekseev D, Grigorieva O, Sysoeva V, Rubina K, Lazarev V, Govorun V (2015) Characterization of secretomes provides evidence for adipose-derived mesenchymal stromal cells subtypes. Stem Cell Res Ther 6:221. CrossRefPubMedPubMedCentralGoogle Scholar
  46. Khabbal J, Kerkelä E, Mitkari B, Raki M, Nystedt J, Mikkonen V, Bergström K, Laitinen S, Korhonen M, Jolkkonen J (2015) Differential clearance of rat and human bone marrow-derived mesenchymal stem cells from the brain after intra-arterial infusion in rats. Cell Transplant 24(5):819–828. CrossRefPubMedGoogle Scholar
  47. Kim SM, Jeong CH, Woo JS, Ryu CH, Lee JH, Jeun SS (2015) In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution. Int J Nanomedicine 11:13–23. CrossRefPubMedPubMedCentralGoogle Scholar
  48. Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN (2018) Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem Cells Transl Med. CrossRefGoogle Scholar
  49. Lebouvier A, Poignard A, Cavet M, Amiaud J, Leotot J, Hernigou P, Rahmouni A, Bierling P, Layrolle P, Rouard H, Chevallier N (2015) Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injection. Stem Cell Res Ther 6:68. CrossRefPubMedPubMedCentralGoogle Scholar
  50. Leibacher J, Dauber K, Ehser S, Brixner V, Kollar K, Vogel A, Spohn G, Schäfer R, Seifried E, Henschler R (2017) Human mesenchymal stromal cells undergo apoptosis and fragmentation after intravenous application in immune-competent mice. Cytotherapy 19(1):61–74CrossRefGoogle Scholar
  51. Lin CM, Gill RG (2016) Direct and indirect allograft recognition: pathways dictating graft rejection mechanisms. Curr Opin Organ Transplant 21(1):40–44CrossRefGoogle Scholar
  52. Lin G, Liu G, Banie L, Wang G, Ning H, Lue TF, Lin C-S (2011a) Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev 20(10):1747–1752. CrossRefPubMedPubMedCentralGoogle Scholar
  53. Lin CS, Lue TF, Illouz YG, Sterodimas A (2011b) Adipose stem cells and regenerative medicine. In: Adipose-derived stem cells: characterization and application in urology. Springer, New York, pp 193–207CrossRefGoogle Scholar
  54. Lin CS, Ning H, Lin G, Lue TF (2012) Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy 14:1159–1163CrossRefGoogle Scholar
  55. Lin CS, Xin ZC, Dai J, Lue TF (2013) Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges. Histol Histopathol 28(9):1109–1116. CrossRefPubMedPubMedCentralGoogle Scholar
  56. Liu JJ, Hu XJ, Li ZR, Yan RH, Li D, Wang J, Shan H (2017a) In vivo bioluminescence imaging of transplanted mesenchymal stromal cells and their rejection mediated by intrahepatic NK cells. Mol Imaging Biol 19(1):31–40. CrossRefPubMedGoogle Scholar
  57. Liu Z, Yago T, Zhang N, Panicker SR, Wang Y, Yao L, Mehta-D’souza P, Xia L, Zhu C, McEver RP (2017b) L-selectin mechanochemistry restricts neutrophil priming in vivo. Nat Commun 8:15196. CrossRefPubMedPubMedCentralGoogle Scholar
  58. Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244CrossRefGoogle Scholar
  59. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S (2011) Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 92(1):26–36. CrossRefPubMedGoogle Scholar
  60. Luk F, de Witte SF, Korevaar SS, Roemeling-van Rhijn M, Franquesa M, Strini T, van den Engel S, Gargesha M, Roy D, Dor FJ, Horwitz EM, de Bruin RW, Betjes MG, Baan CC, Hoogduijn MJ (2016) Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells Dev 25(18):1342–1354. CrossRefPubMedGoogle Scholar
  61. Mäkelä T, Takalo R, Arvola O, Haapanen H, Yannopoulos F, Blanco R, Ahvenjärvi L, Kiviluoma K, Kerkelä E, Nystedt J, Juvonen T, Lehenkari P (2015) Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy 17(4):392–402. CrossRefPubMedGoogle Scholar
  62. Matsushita T, Kibayashi T, Katayama T, Yamashita Y, Suzuki S, Kawamata J, Honmou O, Minami M, Shimohama S (2011) Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci Lett 502(1):41–45. CrossRefPubMedGoogle Scholar
  63. Meseguer-Olmo L, Montellano AJ, Martínez T, Martínez CM, Revilla-Nuin B, Roldán M, Mora CF, López-Lucas MD, Fuente T (2017) Intraarticular and intravenous administration of (99M)Tc-HMPAO-labeled human mesenchymal stem cells ((99M)TC-AH-MSC(S)): in vivo imaging and biodistribution. Nucl Med Biol 46:36–42. CrossRefPubMedGoogle Scholar
  64. Mildmay-White A, Khan W (2017) Cell surface markers on adipose-derived stem cells: a systematic review. Curr Stem Cell Res Ther 12(6):484–492. CrossRefPubMedGoogle Scholar
  65. Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, Hamad OA, Lönnies H, Magnusson PU, Sanchez J, Teramura Y, Nilsson-Ekdahl K, Ringdén O, Korsgren O, Nilsson B, Le Blanc K (2012) Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 30(7):1565–1574. CrossRefPubMedGoogle Scholar
  66. Monsel A, Zhu YG, Gudapati V, Lim H, Lee JW (2016) Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Opin Biol Ther 16(7):859–871. CrossRefPubMedPubMedCentralGoogle Scholar
  67. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV (2011) Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 31:2283–2290PubMedGoogle Scholar
  68. Nong K, Wang W, Niu X, Hu B, Ma C, Bai Y, Wu B, Wang Y, Ai K (2016) Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. Cytotherapy 18(12):1548–1559. CrossRefPubMedGoogle Scholar
  69. Nourshargh S, Alon R (2014) Leukocyte migration into inflamed tissues. Immunity 41(5):694–707. CrossRefPubMedGoogle Scholar
  70. Ophelders DR, Wolfs TG, Jellema RK, Zwanenburg A, Andriessen P, Delhaas T, Ludwig AK, Radtke S, Peters V, Janssen L, Giebel B, Kramer BW (2016) Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia. Stem Cells Transl Med 5(6):754–763. CrossRefPubMedPubMedCentralGoogle Scholar
  71. Oshima K, Aoki N, Kato T, Kitajima K, Matsuda T (2002) Secretion of a peripheral membrane protein, MFG-E8, as a complex with membrane vesicles. Eur J Biochem 269(4):1209–1218CrossRefGoogle Scholar
  72. Pachler K, Lener T, Streif D, Dunai ZA, Desgeorges A, Feichtner M, Öller M, Schallmoser K, Rohde E, Gimona M (2017) A good manufacturing practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. Cytotherapy 19(4):458–472. CrossRefPubMedGoogle Scholar
  73. Packham DK, Fraser IR, Kerr PG, Segal KR (2016) Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine 12:263–269. CrossRefPubMedPubMedCentralGoogle Scholar
  74. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A, ixCELL-DCM Investigators (2016) Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet 387(10036):2412–2421. CrossRefPubMedGoogle Scholar
  75. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, Stern TP, Watling S, Bartel RL (2012) Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 20(6):1280–1286. CrossRefPubMedPubMedCentralGoogle Scholar
  76. Rajalingam R (2012) Overview of the killer cell immunoglobulin-like receptor system. Methods Mol Biol 882:391–414CrossRefGoogle Scholar
  77. Ramot Y, Steiner M, Morad V, Leibovitch S, Amouyal N, Cesta MF, Nyska A (2010) Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology 4(1):98–105. CrossRefPubMedGoogle Scholar
  78. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, Gille J, Henschler R (2006) Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108:3938–3944CrossRefGoogle Scholar
  79. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R (2008) Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 14:181–187CrossRefGoogle Scholar
  80. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM (2017) Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 6(12):2173–2185. CrossRefPubMedPubMedCentralGoogle Scholar
  81. Schafer JL, Müller-Trutwin MC, Reeves RK (2015) NK cell exhaustion: bad news for chronic disease? Oncotarget 6(26):21797–21798CrossRefGoogle Scholar
  82. See F, Seki T, Psaltis PJ, Sondermeijer HP, Gronthos S, Zannettino AC, Govaert KM, Schuster MD, Kurlansky PA, Kelly DJ, Krum H, Itescu S (2011) Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med 15(10):2117–2129. CrossRefPubMedPubMedCentralGoogle Scholar
  83. Singh A, Singh A, Sen D (2016) Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010–2015). Stem Cell Res Ther 7:82. CrossRefPubMedPubMedCentralGoogle Scholar
  84. Skyler JS, Fonseca VA, Segal KR, Rosenstock J, MSB-DM003 Investigators (2015) Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care 38(9):1742–1749. ( Identifier: NCT01843387)CrossRefPubMedPubMedCentralGoogle Scholar
  85. Sood V, Mittal BR, Bhansali A, Singh B, Khandelwal N, Marwaha N, Jain A (2015) Biodistribution of 18F-FDG-labeled autologous bone marrow-derived stem cells in patients with type 2 diabetes mellitus: exploring targeted and intravenous routes of delivery. Clin Nucl Med 40(9):697–700. CrossRefPubMedGoogle Scholar
  86. Spriet M, Hunt GB, Walker NJ, Borjesson DL (2015) Scintigraphic tracking of mesenchymal stem cells after portal, systemic intravenous and splenic administration in healthy beagle dogs. Vet Radiol Ultrasound 56(3):327–334. CrossRefPubMedGoogle Scholar
  87. Stolzing A, Bauer E, Scutt A (2012) Suspension cultures of bone-marrow-derived mesenchymal stem cells: effects of donor age and glucose level. Stem Cells Dev 21:2718–2723CrossRefGoogle Scholar
  88. Tamajusuku AS, Carrillo-Sepulveda MA, Braganhol E, Wink MR, Sarkis JJ, Barreto-Chaves ML, Battastini AM (2006) Activity and expression of ecto-5′-nucleotidase/CD73 are increased by thyroid hormones in vascular smooth muscle cells. Mol Cell Biochem 289:65–72CrossRefGoogle Scholar
  89. Taylor DA, Perin EC, Willerson JT, Zierold C, Resende M, Carlson M, Nestor B, Wise E, Orozco A, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Traverse JH, Cooke JP, Schutt RC, Bhatnagar A, Grant MB, Lai D, Johnstone BH, Sayre SL, Moyé L, Ebert RF, Bolli R, Simari RD, Cogle CR, Cardiovascular Cell Therapy Research Network (CCTRN) (2016) Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction: an embedded cohort evaluation of the FOCUS-CCTRN trial. Cell Transplant 25(9):1675–1687CrossRefGoogle Scholar
  90. Teo GS, Ankrum JA, Martinelli R, Boetto SE, Simms K, Sciuto TE, Dvorak AM, Karp JM, Carman CV (2012) Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 30(11):2472–2486. CrossRefPubMedPubMedCentralGoogle Scholar
  91. Thomas H, Jäger M, Mauel K, Brandau S, Lask S, Flohé SB (2014) Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediat Inflamm 2014:143463. CrossRefGoogle Scholar
  92. Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP (2007) Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 1(2):129–137. CrossRefPubMedGoogle Scholar
  93. Turtzo LC, Budde MD, Dean DD, Gold EM, Lewis BK, Janes L, Lescher J, Coppola T, Yarnell A, Grunberg NE, Frank JA (2015) Failure of intravenous or intracardiac delivery of mesenchymal stromal cells to improve outcomes after focal traumatic brain injury in the female rat. PLoS One 10(5):e0126551. CrossRefPubMedPubMedCentralGoogle Scholar
  94. Valencia J, Blanco B, Yáñez R, Vázquez M, Herrero Sánchez C, Fernández-García M, Rodríguez Serrano C, Pescador D, Blanco JF, Hernando-Rodríguez M, Sánchez-Guijo F, Lamana ML, Segovia JC, Vicente Á, Del Cañizo C, Zapata AG (2016) Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor. Cytotherapy 18(10):1297–1311. CrossRefPubMedGoogle Scholar
  95. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R (2017) Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 18(9). CrossRefGoogle Scholar
  96. Wahid FSA, Ismail NA, Wan Jamaludin WF, Muhamad NA, Mohamad Idris MA, Lai NM (2018) Efficacy and safety of autologous cell-based therapy in patients with no-option critical limb ischaemia: a meta-analysis. Curr Stem Cell Res Ther 13(4):265–283. CrossRefPubMedGoogle Scholar
  97. Walcheck B, Moore KL, McEver RP, Kishimoto TK (1996) Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte accumulation of P-selectin in vitro. J Clin Invest 98:1081–1087CrossRefGoogle Scholar
  98. Wang F, Eid S, Dennis JE, Cooke KR, Auletta JJ, Lee Z (2015) Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation. J Stem Cells Regen Med 11(2):34–43 eCollection 2015PubMedPubMedCentralGoogle Scholar
  99. Wang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B, Zhou J, Heng BC, Zou XH, Ouyang H, Liu H (2017) Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res Ther 8(1):189. CrossRefPubMedPubMedCentralGoogle Scholar
  100. Xiao W, Guo S, Gao C, Dai G, Gao Y, Li M, Wang X, Hu D (2017) A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. Int Heart J 58(2):238–244. CrossRefPubMedGoogle Scholar
  101. Zhu Y, Wang Y, Zhao B, Niu X, Hu B, Li Q, Zhang J, Ding J, Chen Y, Wang Y (2017) Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res Ther 8(1):64. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Federal State Budget Institution “Research Center for Obstetrics, Gynecology and Perinatology” Ministry of Healthcare of the Russian FederationMoscowRussian Federation
  2. 2.Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RASMoscowRussian Federation

Personalised recommendations